Positive anti-tumor effects of recombinant IL-1β have been shown [35], and blockade of IL-1β by treatment with IL-1 receptor antagonist (IL-1Ra) impaired a cancer response by reducing Th1 and tumoricidal macrophage activation [36]. This evidence concerns the gene IL1B and cancer.